Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

06 Jun 2016 - 09 Jun 2016
22 Jun 2016 - 24 Jun 2016
04 Jul 2016 - 06 Jul 2016

Helium-Free, Bench-Top MRI Scanner Draws Interest at Meetings

By BiotechDaily International staff writers
Posted on 21 May 2013
Print article
Ultra-compact, helium-free, preclinical, bench-top magnetic resonance imaging (MRI) scanners have been designed for preclinical imaging of lab animals.

The MR Solutions presented the new scanner at the American Association for Cancer Research (AACR) annual meeting in Washington DC (USA), on April 6-10, 2013, and the International Society for Magnetic Resonance in Medicine (ISMRM) annual meeting in Salt Lake City (UT, USA), on April 20-26, 2013. The new technology spurred a lot of interest for the participants.

Dr. David Taylor, CEO of MR Solutions (Guildford, UK), said, “We were overwhelmed by the interest in this new scanner one of a range to follow soon. We were repeatedly told it was a game changer; producing high quality images without compromise and able to fit within an existing laboratory at a price which is more than competitive.”

MR Solutions, developed the world’s first commercial 3T scanner late in 2012, and in January 2013, introduced two larger bore machines to complete the range. The smaller two of the new scanners, the 16-cm bore, is available now (3T) while the other two machines—31-cm 3T and 72-cm 1.5T—will be available by the end of 2013; orders for these units are already in the works. The new range of three scanners will be able to scan from small to medium-sized animals.

The advantages of these technologic advances are: (1) the scanners provide excellent soft tissue contrast and molecular imaging capabilities. (2) They are very cost-effective as there is no need for all the cryogen cooling equipment. (3) Because they have a very small stray magnetic field, the scanners can be positioned close to other imaging equipment to enable multimodality imaging on the same subject. (4) Lastly, because of the lack of liquid helium cooling and required safety equipment, the scanners are easy to install and need no expensive building alterations.

Related Links:

MR Solutions



Print article

Channels

Genomics/Proteomics

view channel
Image: Follicular helper T-cells (TFH cells, shown in blue) play a crucial role in the maturation of antibody-producing B-cells (shown in green). Activated B-cells give rise germinal centers (shown in red), where mature B-cells proliferate and produce highly specific antibodies against pathogens. Top left: normal germinal center in a mouse tonsil. All others: Germinal centers fail to form when the interaction between ICOS and TBK1 is interrupted (Photo courtesy of Dr. Kok-Fai Kong, La Jolla Institute for Allergy and Immunology).

Molecular Pathway Controlling High-affinity Antibody Production Identified

A molecular pathway has been identified that controls formation of follicular helper T-cells (TFH cells) germinal centers and production of high-affinity antibodies through interaction with the inducible... Read more

Drug Discovery

view channel

Experimental Small-Molecule Anticancer Drug Blocks RAS-binding Domains

The experimental small-molecule anticancer drug rigosertib was shown to block tumor growth by acting as an RAS-mimetic and interacting with the RAS binding domains of RAF kinases, resulting in their inability to bind to RAS, which inhibited the RAS-RAF-MEK pathway. Oncogenic activation of RAS genes due to point mutations... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Business

view channel

European Biotech Agreement to Promote Antigen-Drug Conjugation Technology

Two European biotech companies have joined forces to exploit and commercialize an innovative, site-specific ADC (antigen-drug conjugate) conjugation technology. ProBioGen (Berlin, Germany), a company specializing in the development and manufacture of complex glycoproteins and Eucodis Bioscience (Vienna, Austria), a... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.